For over a decade, Ruth has written for multiple outlets providing patient education, including Health. She has written for health student education companies, collaborating on an anatomy textbook ...
Certain genetic mutations can boost your risk of breast cancer. Here’s what experts say you need to know when making the decision to get tested. Possible anomalies in a breast cancer screening are ...
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...
Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results